Terms: = Brain cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
45 results:
1. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
2. Missense mutation of nras is associated with malignant progression in neurocutaneous melanosis.
Takahashi H; Natsumeda M; Hara N; Koyama A; Shimizu H; Miyashita A; Satake D; Mouri Y; Tsukano J; Kawabe K; Tsukamoto Y; Okada M; Ogura R; Yuki A; Umezu H; Kakita A; Ikeuchi T; Oishi M
Acta Neuropathol Commun; 2024 Jan; 12(1):14. PubMed ID: 38254245
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Features of Resected Melanoma brain Metastases, Clinical Outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
4. Personalized targeted therapy prescription in colorectal cancer using algorithmic analysis of RNA sequencing data.
Sorokin M; Zolotovskaia M; Nikitin D; Suntsova M; Poddubskaya E; Glusker A; Garazha A; Moisseev A; Li X; Sekacheva M; Naskhletashvili D; Seryakov A; Wang Y; Buzdin A
BMC Cancer; 2022 Oct; 22(1):1113. PubMed ID: 36316649
[TBL] [Abstract] [Full Text] [Related]
5. The genomic landscape across 474 surgically accessible epileptogenic human brain lesions.
López-Rivera JA; Leu C; Macnee M; Khoury J; Hoffmann L; Coras R; Kobow K; Bhattarai N; Pérez-Palma E; Hamer H; Brandner S; Rössler K; Bien CG; Kalbhenn T; Pieper T; Hartlieb T; Butler E; Genovese G; Becker K; Altmüller J; Niestroj LM; Ferguson L; Busch RM; Nürnberg P; Najm I; Blümcke I; Lal D
Brain; 2023 Apr; 146(4):1342-1356. PubMed ID: 36226386
[TBL] [Abstract] [Full Text] [Related]
6. Successful treatment with MEK-inhibitor in a patient with nras-related cutaneous skeletal hypophosphatemia syndrome.
Carli D; Cardaropoli S; Tessaris D; Coppo P; La Selva R; Cesario C; Lepri FR; Pullano V; Palumbo M; Ramenghi U; Brusco A; Medico E; De Sanctis L; Ferrero GB; Mussa A
Genes Chromosomes Cancer; 2022 Dec; 61(12):740-746. PubMed ID: 35999193
[TBL] [Abstract] [Full Text] [Related]
7. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract] [Full Text] [Related]
8. Combinatorial effects of azacitidine and trametinib on nras-mutated melanoma.
Hanft KM; Hamed E; Kaiser M; Würtemberger J; Schneider M; Pietsch T; Feige U; Meiss F; Krengel S; Niemeyer C; Hettmer S
Pediatr Blood Cancer; 2022 Apr; 69(4):e29468. PubMed ID: 34866327
[TBL] [Abstract] [Full Text] [Related]
9. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Wang Y; Liu S; Yang Z; Algazi AP; Lomeli SH; Wang Y; Othus M; Hong A; Wang X; Randolph CE; Jones AM; Bosenberg MW; Byrum SD; Tackett AJ; Lopez H; Yates C; Solit DB; Ribas A; Piva M; Moriceau G; Lo RS
Cancer Cell; 2021 Oct; 39(10):1375-1387.e6. PubMed ID: 34416167
[TBL] [Abstract] [Full Text] [Related]
10. First-line treatment of nras-mutated metastatic melanoma with a MEK inhibitor.
Bickel A; Diem S; Flatz L; Stinn B; Siano M
J Cancer Res Ther; 2021; 17(1):276-278. PubMed ID: 33723170
[TBL] [Abstract] [Full Text] [Related]
11. Giant lung metastasis of nras-mutant melanoma in a 24-year-old patient with a history of BRAF-mutant conventional melanoma harboring Spitzoid morphology: a case report.
Vachtenheim J; Kodet R; Fischer O; Kolek V; Strizova Z; Ozaniak A; Simonek J; Stolz A; Pozniak J; Kolarik J; Svorcova M; Vachtenheim J; Lischke R
Diagn Pathol; 2020 Oct; 15(1):132. PubMed ID: 33100226
[TBL] [Abstract] [Full Text] [Related]
12. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via nras/MEK1/ERK1-2 signaling.
Wei Y; Lu C; Zhou P; Zhao L; Lyu X; Yin J; Shi Z; You Y
Neuro Oncol; 2021 Apr; 23(4):611-624. PubMed ID: 32926734
[TBL] [Abstract] [Full Text] [Related]
13. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
14. Longitudinal Monitoring of ctDNA in Patients with Melanoma and brain Metastases Treated with Immune Checkpoint Inhibitors.
Lee JH; Menzies AM; Carlino MS; McEvoy AC; Sandhu S; Weppler AM; Diefenbach RJ; Dawson SJ; Kefford RF; Millward MJ; Al-Ogaili Z; Tra T; Gray ES; Wong SQ; Scolyer RA; Long GV; Rizos H
Clin Cancer Res; 2020 Aug; 26(15):4064-4071. PubMed ID: 32321716
[TBL] [Abstract] [Full Text] [Related]
15. Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment.
Pepe F; Pisapia P; Del Basso de Caro ML; Conticelli F; Malapelle U; Troncone G; Martinez JC
Histol Histopathol; 2020 Jul; 35(7):741-749. PubMed ID: 31872418
[TBL] [Abstract] [Full Text] [Related]
16. Neurocutaneous Melanocytosis and Leptomeningeal Melanoma.
Mitre V; Heym K; Clark GD; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e195-e197. PubMed ID: 31764519
[TBL] [Abstract] [Full Text] [Related]
17. Principles of Targeted Therapy for Melanoma.
Sun J; Carr MJ; Khushalani NI
Surg Clin North Am; 2020 Feb; 100(1):175-188. PubMed ID: 31753111
[TBL] [Abstract] [Full Text] [Related]
18. The antibiotic clofoctol suppresses glioma stem cell proliferation by activating KLF13.
Hu Y; Zhang M; Tian N; Li D; Wu F; Hu P; Wang Z; Wang L; Hao W; Kang J; Yin B; Zheng Z; Jiang T; Yuan J; Qiang B; Han W; Peng X
J Clin Invest; 2019 May; 129(8):3072-3085. PubMed ID: 31112526
[TBL] [Abstract] [Full Text] [Related]
19. Survival and prognostic factors in surgically treated brain metastases.
Kavouridis VK; Harary M; Hulsbergen AFC; Lo YT; Reardon DA; Aizer AA; Iorgulescu JB; Smith TR
J Neurooncol; 2019 Jun; 143(2):359-367. PubMed ID: 30989623
[TBL] [Abstract] [Full Text] [Related]
20. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract] [Full Text] [Related]
[Next]
